First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...
Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 ...
Chris Planto has rejoined Rate as VP of mortgage lending in Houston after serving as a senior loan officer at CrossCountry ...
Zacks Investment Research on MSN
OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands
OPKO Health, Inc. OPK posted earnings per share of 3 cents for the third quarter of 2025, flat year over year. Earnings beat ...
Regeneron and ModeX Therapeutics have joined forces in a collaboration worth over one billion dollars to develop ...
US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...
ModeX Therapeutics enters research collaboration with Regeneron to develop multispecific antibodies for select therapeutic indications: Weston, Massachusetts Thursday, October 30, ...
Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...
MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.
Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type 2I/R9, the company was back at it again, this time reporting positive ...
With a modest $7 million up front but an ultimate payout potentially topping $1 billion on the line, Modex Therapeutics Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback